Skip to main content
PIQRAY is the first and only therapy for aBC patients with a PIK3CA mutation

The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

PIQRAY mPFS data

See the efficacy data

Learn more about the results of the pivotal SOLAR-1 trial.

 

 

See the data →

PIK3CA testing

Testing comes first

See the importance of testing for PIK3CA mutations.

 

 

Learn more →

PIQRAY Safety Profile

Review the safety profile

Explore the serious and most common adverse reactions and more safety information.

 

Review safety profile →

Efficacy & safety

Learn about PIQRAY study results and what they mean to both oncologists and their patients in this roundtable discussion between Dr Dejan Juric, Dr Jules Cohen, Dr Mohammad Jahanzeb, and Dr Chaitali Nangia.

View more expert videos 

Build your own AR management guide

AR Management Tool: Find the info you need

Answer a few questions about the select adverse reaction(s) your patient is experiencing to get customized management guidance.

*Unless a recurrence or unmanageable toxicity occurs, per HR+/HER2- MBC American Society of Clinical Oncology® Guideline Update 2021.

Important Safety Information

PIQRAY is contraindicated in patients with severe hypersensitivity to it or any of its components. 

Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia...

Indication

PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 9, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. 2. Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959-3977.